Ernest Pedapati
Professor, UC Department of Psychiatry and Behavioral Neuroscience Cincinnati Children’s Hospital
Seminars
Tuesday 15th September 2026
Decision Grade EEG Biomarkers to De Risk Early Neuropsychiatric Drug Development: Case Study in Fragile X & Schizophrenia
1:00 pm
- Using EEG as a sensitive, translational readout of drug-target engagement in small first in human studies across Fragile X, schizophrenia, and other brain disorders
- Demonstrating rapid rescue and normalisation of disease relevant EEG signals following acute dosing and linking these changes to clinically meaningful cognitive outcomes
- Pairing EEG biomarkers with regulatory acceptable endpoints, including NIH Toolbox measures, to strengthen confidence in early proof of concept
- Applying EEG based responder identification to de risk progression into larger Phase 2 and 3 trials across heterogeneous neuropsychiatric populations
